Full text is available at the source.
Abstract
Rapid weight loss induced by GLP-1 receptor agonists is associated with pronounced muscle loss.
- GDF8 (myostatin) and activin A (ActA) are identified as negative regulators of muscle mass.
- Antibodies that block GDF8 and ActA may have a role in counteracting muscle loss.
- The study aims to evaluate the effects of two specific antibodies on weight and muscle loss during semaglutide treatment.
Simplified